Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT02241590Phase 4Unknown

Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

Role: collaborator

NCT02241616Phase 4Unknown

Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

Role: collaborator

All 2 trials loaded